PERTH, AUSTRALIA – 9 December 2019: SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oromucosal drug delivery, is pleased to announce that it has entered into a feasibility agreement with SANOFI-AVENTIS GROUPE (SANOFI) to investigate the feasibility of SUDA’s OroMist Technology and SANOFI selected active ingredient
The agreement is for SUDA to carry out a fully-funded feasibility study that will terminate on March 30th, 2021. As a feasibility study, this study is not intended to generate significant revenue.
Based on the outcomes of this feasibility study, SANOFI and SUDA may enter into further collaboration.
For more information please download the document.
Download this document
